Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
Special Offer: Just $199
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
QQQ   283.69 (-1.13%)
AAPL   144.51 (-2.43%)
MSFT   242.18 (-2.15%)
META   109.35 (-1.85%)
GOOGL   96.19 (-1.30%)
AMZN   94.16 (+0.80%)
TSLA   184.54 (+0.92%)
NVDA   160.20 (-1.54%)
NIO   10.25 (+0.79%)
BABA   76.14 (+0.85%)
AMD   73.47 (-2.22%)
T   18.86 (-1.36%)
MU   56.22 (-3.75%)
CGC   3.41 (-6.83%)
F   13.72 (-2.56%)
GE   86.07 (-2.35%)
DIS   96.25 (-2.65%)
AMC   7.15 (-4.79%)
PYPL   80.70 (+0.77%)
PFE   49.40 (+0.39%)
NFLX   283.40 (-0.75%)
QQQ   283.69 (-1.13%)
AAPL   144.51 (-2.43%)
MSFT   242.18 (-2.15%)
META   109.35 (-1.85%)
GOOGL   96.19 (-1.30%)
AMZN   94.16 (+0.80%)
TSLA   184.54 (+0.92%)
NVDA   160.20 (-1.54%)
NIO   10.25 (+0.79%)
BABA   76.14 (+0.85%)
AMD   73.47 (-2.22%)
T   18.86 (-1.36%)
MU   56.22 (-3.75%)
CGC   3.41 (-6.83%)
F   13.72 (-2.56%)
GE   86.07 (-2.35%)
DIS   96.25 (-2.65%)
AMC   7.15 (-4.79%)
PYPL   80.70 (+0.77%)
PFE   49.40 (+0.39%)
NFLX   283.40 (-0.75%)
QQQ   283.69 (-1.13%)
AAPL   144.51 (-2.43%)
MSFT   242.18 (-2.15%)
META   109.35 (-1.85%)
GOOGL   96.19 (-1.30%)
AMZN   94.16 (+0.80%)
TSLA   184.54 (+0.92%)
NVDA   160.20 (-1.54%)
NIO   10.25 (+0.79%)
BABA   76.14 (+0.85%)
AMD   73.47 (-2.22%)
T   18.86 (-1.36%)
MU   56.22 (-3.75%)
CGC   3.41 (-6.83%)
F   13.72 (-2.56%)
GE   86.07 (-2.35%)
DIS   96.25 (-2.65%)
AMC   7.15 (-4.79%)
PYPL   80.70 (+0.77%)
PFE   49.40 (+0.39%)
NFLX   283.40 (-0.75%)
QQQ   283.69 (-1.13%)
AAPL   144.51 (-2.43%)
MSFT   242.18 (-2.15%)
META   109.35 (-1.85%)
GOOGL   96.19 (-1.30%)
AMZN   94.16 (+0.80%)
TSLA   184.54 (+0.92%)
NVDA   160.20 (-1.54%)
NIO   10.25 (+0.79%)
BABA   76.14 (+0.85%)
AMD   73.47 (-2.22%)
T   18.86 (-1.36%)
MU   56.22 (-3.75%)
CGC   3.41 (-6.83%)
F   13.72 (-2.56%)
GE   86.07 (-2.35%)
DIS   96.25 (-2.65%)
AMC   7.15 (-4.79%)
PYPL   80.70 (+0.77%)
PFE   49.40 (+0.39%)
NFLX   283.40 (-0.75%)
NYSE:RMD

ResMed - RMD Stock Forecast, Price & News

$225.58
-4.34 (-1.89%)
(As of 11/28/2022 01:56 PM ET)
Add
Compare
Today's Range
$225.28
▼
$230.62
50-Day Range
$208.94
▼
$233.97
52-Week Range
$189.40
▼
$268.77
Volume
8,048 shs
Average Volume
553,389 shs
Market Capitalization
$33.04 billion
P/E Ratio
42.16
Dividend Yield
0.77%
Price Target
$267.00

ResMed MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
18.1% Upside
$267.00 Price Target
Short Interest
Healthy
0.74% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
-1.04
Upright™ Environmental Score
News Sentiment
0.43mentions of ResMed in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$16.85 M Sold Last Quarter
Proj. Earnings Growth
12.65%
From $6.48 to $7.30 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.04 out of 5 stars

Medical Sector

39th out of 1,040 stocks

Surgical & Medical Instruments Industry

2nd out of 103 stocks

See Top Rated MarketRank™ Stocks Here
RMD stock logo

About ResMed (NYSE:RMD) Stock

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Receive RMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter.

RMD Stock News Headlines

November 22, 2022 | finance.yahoo.com
ResMed Completes Acquisition of MEDIFOX DAN, a German Leader in Out-of-Hospital Care Management Software Solutions
November 19, 2022 | americanbankingnews.com
Insider Selling: ResMed Inc. (NYSE:RMD) CEO Sells $1,274,832.00 in Stock
November 10, 2022 | finance.yahoo.com
Here's Why Shareholders Will Not Be Complaining About ResMed Inc.'s (NYSE:RMD) CEO Pay Packet
October 27, 2022 | finance.yahoo.com
ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2023
October 17, 2022 | fool.com.au
2 classic healthcare ASX shares priced to buy now: expert - The Motley Fool Australia
October 17, 2022 | globenewswire.com
CPAP Devices Market Size is projected to reach USD 5254.51 million by 2030, growing at a CAGR of 7.4%: Straits Research - GlobeNewswire
October 14, 2022 | fool.com.au
What's the outlook for ASX healthcare shares in Q2? - The Motley Fool Australia
October 14, 2022 | benzinga.com
ResMed to Report First Quarter Fiscal 2023 Earnings on October 27, 2022 - ResMed (NYSE:RMD) - Benzinga
October 13, 2022 | finance.yahoo.com
ResMed to Report First Quarter Fiscal 2023 Earnings on October 27, 2022
October 12, 2022 | globenewswire.com
Sleep Apnea Devices Market Size to Surpass US$ 12.86 Billion by 2030 - Growth Plus Reports - GlobeNewswire
October 7, 2022 | nytimes.com
How a Hasidic Wedding in the UAE Went Viral on Instagram - The New York Times
September 26, 2022 | finance.yahoo.com
ResMed (RMD) Gains on Product Uptake Even as Expenses Rise
September 25, 2022 | fool.com.au
Not all ASX 200 shares are getting hammered today. Here are some winners - The Motley Fool Australia
September 25, 2022 | fool.com.au
Experts names the blue chip ASX 200 shares to buy - The Motley Fool Australia
September 22, 2022 | benzinga.com
Hopeful Golden Cross Forms On ResMed's Chart - ResMed (NYSE:RMD) - Benzinga
September 21, 2022 | fool.com.au
Experts name 2 outstanding ASX 200 shares to buy right now - The Motley Fool Australia
September 15, 2022 | finance.yahoo.com
Insights on the Respiratory Devices Global Market to 2028 - Featuring Philips Healthcare, ResMed, Medtronic and Masimo Among Others - Yahoo Finance
September 9, 2022 | globenewswire.com
Connected Health and Wellness Solutions Global Market Report 2022 - GlobeNewswire
September 6, 2022 | benzinga.com
Resmed Inc. (RMD) – ResMed Announces Participation in the 20th Annual Morgan Stanley Global Healthcare Conference - Benzinga
September 6, 2022 | nasdaq.com
A Look At The Intrinsic Value Of ResMed Inc. (NYSE:RMD) - Nasdaq
September 4, 2022 | globenewswire.com
Over 480 Million People Estimated to Have COPD, World's - GlobeNewswire
September 4, 2022 | benzinga.com
Resmed Inc. (RMD) – Over 480 Million People Estimated to Have COPD, World's Third Deadliest Disease, ResM - Benzinga
August 31, 2022 | fool.com
ResMed (NYSE: RMD)
August 31, 2022 | nasdaq.com
Reasons Why You Should Retain ResMed (RMD) Stock For Now - Nasdaq
August 30, 2022 | marketwatch.com
ResMed Inc. stock falls Tuesday, still outperforms market - MarketWatch
See More Headlines
Receive RMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter.

RMD Company Calendar

Ex-Dividend for 9/22 Dividend
8/17/2022
Dividend Payable
9/22/2022
Last Earnings
10/27/2022
Ex-Dividend for 12/15 Dividend
11/09/2022
Today
11/28/2022
Dividend Payable
12/15/2022
Next Earnings (Estimated)
1/26/2023
Fiscal Year End
6/30/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NYSE:RMD
CUSIP
76115210
CIK
943819
Web
www.resmed.com
Phone
(858) 836-5000
Fax
858-836-5501
Employees
8,160
Year Founded
1989

Price Target and Rating

Average Stock Price Forecast
$267.00
High Stock Price Forecast
$280.00
Low Stock Price Forecast
$245.00
Forecasted Upside/Downside
+18.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
10 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$5.35
Trailing P/E Ratio
42.16
Forward P/E Ratio
34.81
P/E Growth
1.48
Net Income
$779.44 million
Net Margins
21.70%
Pretax Margin
26.58%
Return on Equity
25.75%
Return on Assets
17.09%

Debt

Debt-to-Equity Ratio
0.23
Current Ratio
2.94
Quick Ratio
1.69

Sales & Book Value

Annual Sales
$3.58 billion
Price / Sales
9.23
Cash Flow
$7.01 per share
Price / Cash Flow
32.20
Book Value
$22.97 per share
Price / Book
9.82

Miscellaneous

Outstanding Shares
146,484,000
Free Float
144,448,000
Market Cap
$33.04 billion
Optionable
Optionable
Beta
0.47

Social Links


Key Executives

  • Dr. Peter C. Farrell A.M. (Age 80)
    AM, B.E., BE (Hons), Ph.D., ScD, Founder & Non-Exec. Chairman
    Comp: $430.56k
  • Mr. Michael J. Farrell BEMr. Michael J. Farrell BE (Age 50)
    MBA, SM, CEO & Director
    Comp: $2.66M
  • Mr. Robert A. Douglas (Age 62)
    Pres & COO
    Comp: $1.82M
  • Mr. Brett A. SandercockMr. Brett A. Sandercock (Age 55)
    Chief Financial Officer
    Comp: $891.39k
  • Mr. David B. PendarvisMr. David B. Pendarvis (Age 63)
    Chief Admin. Officer, Global Gen. Counsel & Corp. Sec.
    Comp: $1.11M
  • Mr. Kaushik Ghoshal (Age 54)
    Pres of SaaS Bus.
    Comp: $1.11M
  • Ms. Urvashi Tyagi
    Chief Technology Officer
  • Ms. Constance C. Bienfait
    Director of Investor Relations
  • Ms. Amy Wakeham
    VP of Investor Relations & Corp. Communications
  • Ms. Vered Keisar
    Chief People Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













RMD Stock - Frequently Asked Questions

Should I buy or sell ResMed stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last year. There are currently 4 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RMD shares.
View RMD analyst ratings or view top-rated stocks.

What is ResMed's stock price forecast for 2023?

10 analysts have issued 1 year target prices for ResMed's stock. Their RMD share price forecasts range from $245.00 to $280.00. On average, they expect the company's stock price to reach $267.00 in the next twelve months. This suggests a possible upside of 16.1% from the stock's current price.
View analysts price targets for RMD or view top-rated stocks among Wall Street analysts.

How have RMD shares performed in 2022?

ResMed's stock was trading at $260.48 at the beginning of 2022. Since then, RMD shares have decreased by 11.7% and is now trading at $229.92.
View the best growth stocks for 2022 here.

When is ResMed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, January 26th 2023.
View our RMD earnings forecast.

How were ResMed's earnings last quarter?

ResMed Inc. (NYSE:RMD) issued its quarterly earnings results on Thursday, October, 27th. The medical equipment provider reported $1.51 EPS for the quarter, hitting the consensus estimate of $1.51. The medical equipment provider earned $950.30 million during the quarter, compared to analyst estimates of $946.07 million. ResMed had a trailing twelve-month return on equity of 25.75% and a net margin of 21.70%. The company's quarterly revenue was up 5.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.51 EPS.
Read the conference call transcript.

How often does ResMed pay dividends? What is the dividend yield for ResMed?

ResMed announced a quarterly dividend on Thursday, October 27th. Stockholders of record on Thursday, November 10th will be paid a dividend of $0.44 per share on Thursday, December 15th. This represents a $1.76 dividend on an annualized basis and a yield of 0.77%. The ex-dividend date of this dividend is Wednesday, November 9th.
Read our dividend analysis for RMD.

Is ResMed a good dividend stock?

ResMed (NYSE:RMD) pays an annual dividend of $1.76 per share and currently has a dividend yield of 0.77%. The company has been increasing its dividend for 2 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 32.90%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, RMD will have a dividend payout ratio of 24.11% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for RMD.

What is Mick Farrell's approval rating as ResMed's CEO?

284 employees have rated ResMed Chief Executive Officer Mick Farrell on Glassdoor.com. Mick Farrell has an approval rating of 92% among the company's employees. This puts Mick Farrell in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ResMed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ResMed investors own include NVIDIA (NVDA), Walt Disney (DIS), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Adobe (ADBE), Visa (V), Alibaba Group (BABA), PayPal (PYPL) and QUALCOMM (QCOM).

What is ResMed's stock symbol?

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

Who are ResMed's major shareholders?

ResMed's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (11.10%), BlackRock Inc. (9.12%), State Street Corp (4.41%), WCM Investment Management LLC (3.97%), Ownership Capital B.V. (1.01%) and Bank of New York Mellon Corp (0.87%). Insiders that own company stock include Brett Sandercock, Carol Burt, Dave Michaud, David Pendarvis, James Hollingshead, Justin Leong, Lucile Blaise, Michael J Farrell, Peter C Farrell, Rajwant Sodhi, Robert Andrew Douglas and Ronald R Taylor.
View institutional ownership trends.

How do I buy shares of ResMed?

Shares of RMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ResMed's stock price today?

One share of RMD stock can currently be purchased for approximately $229.92.

How much money does ResMed make?

ResMed (NYSE:RMD) has a market capitalization of $33.68 billion and generates $3.58 billion in revenue each year. The medical equipment provider earns $779.44 million in net income (profit) each year or $5.35 on an earnings per share basis.

How many employees does ResMed have?

The company employs 8,160 workers across the globe.

How can I contact ResMed?

ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The official website for the company is www.resmed.com. The medical equipment provider can be reached via phone at (858) 836-5000, via email at investorrelations@resmed.com, or via fax at 858-836-5501.

This page (NYSE:RMD) was last updated on 11/28/2022 by MarketBeat.com Staff